RESEARCH & TREATMENT

Three-quarters of CAC2 member organizations fund essential research projects related to childhood and AYA cancer.  The coverage is deep and broad:  across the spectrum of development, from basic research through to clinical trials; across a wide range of topics, including data sharing, crucial medicines, psycho-social standards, and survivorship; and across the country and around the world.

Research funded by our members is crucial to discovering more effective treatments that minimize side effects and increase quality of life during and after treatment.  Most importantly, that research investment represents a shared aim to find cures for all types of childhood cancer.  CAC2 celebrates each and every member’s efforts to help close the large and persistent gap between funding needs to achieve this goal andavailable resources.

CAC2 doesn’t just applaud our member’s individual efforts but strives to act as a catalyst for research members to work collaboratively to effect positive change in the childhood cancer research community.  The Research and Treatment Interest Group has a four-pronged strategy for achieving this goal.

Research and Treatment Interest Group Strategy

Webinars, Conferences, and News
Information Repositories
Co-Funding Opportunities
Ethics and Best Practices

The Research and Treatment interest Group strives to establish CAC2 as a credible resource for moving the field of pediatric cancer forward through thoughtful, progressive studies and projects.

ALL member organizations with a research interest or focus are encouraged to participate in the work of the CAC2 Research and Treatment Interest Group. Volunteers are welcome to join a committee on a rolling basis. Please contact us at  for more information.

“Talent wins games, but teamwork and intelligence win championships.” – Michael Jordan

Ethics Think Tank
Foundation Match
ICRP Database
CAC2 Research Conference Proceedings
Research News

Latest CAC2 and Community News

CAC2 Childhood Cancer Community News Digest (April 1-7)

Assorted News from the Last Week: FDA announced its Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet virtually on 22 May to discuss provisions in the 2017 FDA Reauthorization Act that require sponsors of adult cancer drug ...

CAC2 Childhood Cancer Community News Digest (March 25-31)

Assorted News from the Last Week: Cancer is far more likely to be caused by “tumor-suppressor” genes than by one gene run amok.  Interestingly, last week Nature reported that researchers from St. Jude had stumbled on a new way of ...

CAC2 Childhood Cancer Community News Digest (March 18-24)

Assorted News from the Last Week: The White House Office of Science and Technology Policy (OSTP) has announced that the Pediatric Cancer Data Commons (PCDC) at the University of Chicago is one of five winners of the 2023 OSTP Year ...